Targeted Alpha-emitter Therapy of PRRT Naive Neuroendocrine Tumor Patients
Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
Multicenter Phase 2 study of 212Pb-DOTAMTATE enrolling adult subjects with positive
somatostatin positive neuroendocrine tumors with no prior history of peptide receptor
radionuclide therapy (PRRT naive)